Urogen Pharma (NASDAQ:URGN) Receives $31.43 Average Target Price from Analysts

Key Points

• Urogen Pharma has received an average consensus recommendation of "Buy" from eight brokerages, with six analysts rating it a buy and one a strong buy, while the average 12-month price target is approximately $31.43.
• The company reported a quarterly loss per share of ($1.05), which was worse than analysts' expectations but had revenue of $24.22 million, surpassing the consensus estimate.
• Insider trading activity shows that executives have sold a significant number of shares, with a total of 17,833 shares sold in the last 90 days, indicating potential shifts in confidence among company insiders.

Urogen Pharma (NASDAQ:URGN - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $31.4286.

A number of research analysts have issued reports on the stock. D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Urogen Pharma in a report on Tuesday, August 5th. HC Wainwright reduced their target price on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Oppenheimer set a $31.00 target price on shares of Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. Guggenheim restated a "buy" rating and issued a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Finally, Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th.

Insider Activity

In other news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the transaction, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This represents a 6.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Jason Drew Smith sold 7,522 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel owned 41,492 shares in the company, valued at approximately $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,833 shares of company stock worth $457,467. Insiders own 4.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its holdings in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company's stock valued at $94,000 after buying an additional 5,571 shares during the period. Soleus Capital Management L.P. purchased a new position in Urogen Pharma in the second quarter valued at approximately $29,934,000. Man Group plc purchased a new position in Urogen Pharma in the second quarter valued at approximately $196,000. BNP Paribas Financial Markets raised its holdings in Urogen Pharma by 2,874.4% in the second quarter. BNP Paribas Financial Markets now owns 71,921 shares of the company's stock valued at $985,000 after buying an additional 69,503 shares during the period. Finally, Bank of America Corp DE raised its holdings in Urogen Pharma by 34.7% in the second quarter. Bank of America Corp DE now owns 265,117 shares of the company's stock valued at $3,632,000 after buying an additional 68,315 shares during the period. Hedge funds and other institutional investors own 91.29% of the company's stock.

Urogen Pharma Price Performance

NASDAQ:URGN traded down $0.37 on Wednesday, reaching $19.71. The stock had a trading volume of 684,044 shares, compared to its average volume of 1,350,729. The company has a market cap of $911.78 million, a price-to-earnings ratio of -5.94 and a beta of 1.12. The firm's fifty day moving average is $15.46 and its two-hundred day moving average is $11.66. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $21.01.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The firm had revenue of $24.22 million during the quarter, compared to analysts' expectations of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. As a group, research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.